TARGETED THERAPY FOR BRAFV600E MUTANT MALIGNANT ASTROCYTOMA

被引：0
|
作者：
Nicolaides, Theodore [1 ]
Hariono, Sujatmi [1 ]
Barkovich, Krister [1 ]
Hashizume, Rintaro [1 ]
Rowitch, David [1 ]
Weiss, William [1 ]
Sheer, Denise [2 ]
Baker, Suzanne [3 ]
Paugh, Barbara [3 ]
Waldman, Todd [4 ]
Li, Huifang [4 ]
Jones, Chris [5 ]
Forshew, Tim [2 ]
James, David [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ London, London, England
[3] St Jude Childrens Hosp, Memphis, TN 38105 USA
[4] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[5] Inst Canc Res, Sutton, Surrey, England
来源：
NEURO-ONCOLOGY | 2011年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [31] Should BRAFV600E Be Tested in Primary or Metastatic Malignant Melanoma?
    Santos-Briz, A.
    Godoy, E.
    Arango, L.
    Antunez, P.
    Alcaraz, F.
    Fernandez, E.
    Ludena, M. D.
    [J]. MODERN PATHOLOGY, 2013, 26 : 120A - 120A
  • [32] Should BRAFV600E Be Tested in Primary or Metastatic Malignant Melanoma?
    Santos-Briz, A.
    Godoy, E.
    Arango, L.
    Antunez, P.
    Alcaraz, E.
    Fernandez, E.
    Ludena, M. D.
    [J]. LABORATORY INVESTIGATION, 2013, 93 : 120A - 120A
  • [33] Advances in the therapy of BRAFV600E metastatic colorectal cancer
    Jin, Zhaohui
    Sinicrope, Frank A.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (09) : 823 - 829
  • [34] HSP90 INHIBITION OVERCOMES RESISTANCE TO MOLECULAR TARGETED THERAPY IN BRAFV600E MUTANT HIGH-GRADE GLIOMA
    Tateishi, Kensuke
    Sasame, Jo
    Naoki, Ikegaya
    Natsumeda, Manabu
    Kawazu, Masahito
    Wakimoto, Hiroaki
    Cahill, Daniel
    Yamamoto, Tetsuya
    [J]. NEURO-ONCOLOGY, 2022, 24 : 209 - 209
  • [35] A SAFETY STUDY OF VEMURAFENIB, AN ORAL INHIBITOR OF BRAFV600E, IN CHILDREN WITH RECURRENT/REFRACTORY BRAFV600E MUTANT BRAIN TUMORS: PNOC-002
    Nicolaides, Theo
    Nazemi, Kellie
    Crawford, John
    Kilburn, Lindsay
    Minturn, Jane
    Gajjar, Amar
    Gauvain, Karen
    Leary, Sarah
    Dhall, Girish
    Aboian, Mariam
    Robinson, Giles
    Molinaro, Annette
    Mueller, Sabine
    Prados, Michael
    [J]. NEURO-ONCOLOGY, 2017, 19 : 188 - 188
  • [36] Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer
    Huijberts, Sanne C. F. A.
    van Geel, Robin M. J. M.
    Bernards, Rene
    Beijnen, Jos H.
    Steeghs, Neeltje
    [J]. FUTURE ONCOLOGY, 2020, 16 (06) : 161 - 174
  • [37] The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
    Mauri, Gianluca
    Bonazzina, Erica
    Amatu, Alessio
    Tosi, Federica
    Bencardino, Katia
    Gori, Viviana
    Massihnia, Daniela
    Cipani, Tiziana
    Spina, Francesco
    Ghezzi, Silvia
    Siena, Salvatore
    Sartore-Bianchi, Andrea
    [J]. CANCERS, 2021, 13 (01) : 1 - 15
  • [38] MAPK PATHWAY BLOCKADE PRIMES BRAFV600E MUTANT GLIOMA FOR IMMUNOTHERAPY
    Grossauer, Stefan
    Koeck, Katharina
    Murphy, Nicole
    Phillips, Joanna
    Wrainwright, Derek
    Okada, Hideho
    Mueller, Sabine
    James, C. David
    Nicolaides, Theo
    Petritsch, Claudia K.
    [J]. NEURO-ONCOLOGY, 2016, 18 : 90 - 90
  • [39] BRAFV600E mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients
    Sellar, Rob S.
    Fend, Falko
    Akarca, Ayse U.
    Agostinelli, Claudio
    Shende, Vishvesh
    Quintanilla-Martinez, Leticia
    Stein, Harald
    Pileri, Stefano A.
    Linch, David
    Marafioti, Teresa
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (02) : 282 - 285
  • [40] A biomarker of response to therapy in metastatic BRAFV600E colorectal cancers
    [J]. Nature Medicine, 2022, 28 : 2015 - 2016
12345